Efficacy, Safety, and Risk Factors for Failure of Standalone Ab Interno Gelatin Microstent Implantation Versus Standalone Trabeculectomy
Overview
Authors
Affiliations
Purpose: To compare the efficacy, safety, and risk factors for failure of standalone ab interno gelatin microstent implantation with mitomycin C (MMC) versus trabeculectomy with MMC.
Design: International, multicenter, retrospective interventional cohort study.
Participants: Three hundred fifty-four eyes of 293 patients (185 microstent and 169 trabeculectomy) with no prior incisional surgery.
Methods: Consecutive eyes with uncontrolled glaucoma underwent microstent or trabeculectomy surgery from January 1, 2011 through July 31, 2015 at 4 academic ophthalmology centers: Toronto, Canada; Frankfurt, Germany; Salzburg, Austria; and Leuven, Belgium.
Main Outcome Measures: Primary outcome measure was hazard ratio (HR) of failure, with failure defined as 2 consecutive intraocular pressure (IOP) readings of <6 mmHg with vision loss or >17 mmHg without glaucoma medications (complete success) at least 1 month after surgery despite in-clinic interventions (including needling). Secondary outcome measures included IOP thresholds of 6 to 14 mmHg and 6 to 21 mmHg and same thresholds allowing for medications (qualified success), interventions, complications, and reoperations.
Results: Baseline characteristics were similar, except more men (56% vs. 43%), younger patients (average, by 3 years), better preoperative visual acuity (22% vs. 32% with 0.4 logarithm of the minimum angle of resolution vision or worse), and more trabeculoplasty (52% vs. 30%) among microstent eyes. The adjusted HR of failure of the microstent relative to trabeculectomy was 1.2 (95% confidence interval [CI], 0.7-2.0) for complete success and 1.3 (95% CI, 0.6-2.8) for qualified success, and similar for other outcomes. Time to 25% failure was 11.2 months (95% CI, 6.9-16.1 months) and 10.6 months (95% CI, 6.8-16.2 months) for complete success and 30.3 months (95% CI, 19.0-∞ months) and 33.3 months (95% CI, 25.7-46.2 months) for qualified success. Overall, white ethnicity was associated with decreased risk of failure (adjusted HR, 0.49; 95% CI, 0.25-0.96), and diabetes was associated with increased risk of failure (adjusted HR, 4.21; 95% CI, 2.10-8.45). There were 117 and 165 distinct interventions: 43% and 31% underwent needling, respectively, and 50% of trabeculectomy eyes underwent laser suture lysis. There were 22 and 30 distinct complications, although most were transient. Ten percent and 5% underwent reoperation (P = 0.11).
Conclusions: There was no detectable difference in risk of failure and safety profiles between standalone ab interno microstent with MMC and trabeculectomy with MMC.
Short-term efficacy and safety of A-stream glaucoma shunt: a 6-month study.
Park H, Lee E, Han J, Rho S, Shin J, Park D Eye (Lond). 2025; .
PMID: 39979615 DOI: 10.1038/s41433-025-03728-y.
Ahmed I, Vera V, Stalmans I, Fea A, Mansouri K, Gu X BMJ Open Ophthalmol. 2025; 10(1).
PMID: 39915236 PMC: 11804186. DOI: 10.1136/bmjophth-2024-001696.
Assessing XEN microstent's one-year efficacy: independent of site variability.
Bormann C, Busch C, Rehak M, Scharenberg C, Ziemssen F, Unterlauft J Int J Ophthalmol. 2025; 18(1):86-93.
PMID: 39829609 PMC: 11672093. DOI: 10.18240/ijo.2025.01.10.
Park H, Cho H, Kim H, Lee J, Kim C, Bae H Korean J Ophthalmol. 2024; 39(1):1-13.
PMID: 39715709 PMC: 11856050. DOI: 10.3341/kjo.2024.0091.
Reichel F, Guggenberger V, Faber H, Neubauer J, Voykov B J Ophthalmol. 2024; 2024:3895054.
PMID: 39492955 PMC: 11531357. DOI: 10.1155/2024/3895054.